EffePharm
EffePharm is a Shanghai-based B2B biotechnology company that supplies science-backed bioactive ingredients (NMN, NMNH, and liposomal formulations) and licenses proprietary delivery technologies to nutraceutical, functional food, and personal care brands in 50+ countries.
- Company typePrivate
- Founded2017
- HeadquartersShanghai, China
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What EffePharm does
EffePharm is a privately held Shanghai-based biotechnology company founded in 2017 that operates exclusively as a B2B supplier of science-backed bioactive ingredients to the nutraceutical, functional food, and personal care industries. The company sells bulk ingredients and licenses proprietary delivery technologies and trademarked ingredient brands to supplement manufacturers, health product companies, and personal care brands across more than 50 countries, with trademark licensing relationships to 110+ brands and a customer base cited at 3,000+ clients or 600+ business partners depending on the source.
The company's core technology platform is the Effe-PLUS Platform, which comprises three proprietary delivery systems: LipoAvail® liposomal technology, CelleSperse® micelles technology, and EncapCirc® microencapsulation technology. These are applied across a portfolio that includes flagship NAD+ precursor ingredients UTHEVER® NMN (world's first clinically proven NMN brand, FDA NDI 1444) and UthPeak® NMNH (world's first self-GRAS approved reduced NMN), along with ten LipoAvail® liposomal sub-products spanning NMN, NAD+, Glutathione, Resveratrol, Silymarin, Vitamin C, Curcumin, CoQ10, Iron, and PEA. Additional ingredient brands include Biofolate® (L-5-MTHF-Ca), SuperMide™ (spermidine), ErgoX™ (ergothioneine), ApiAge™ (apigenin), Fisetin, and Palmitoylethanolamide (PEA). The company holds 20+ patents and manufactures in cGMP and ISO 9001 certified facilities.
EffePharm generates revenue through three streams: bulk ingredient sales (per-kilogram pricing of raw materials), technology and trademark licensing (the 'Uth' series and delivery technology trademarks licensed to formulation partners), and customized formulation services (scientific advisory and bespoke formulation development). The company pursues a B2B go-to-market via direct sales, regional offices (Shanghai HQ and Hong Kong regional office), and presence at major industry trade shows (SupplySide Global, Vitafoods Europe/Asia, HNC, CPHI, Hi Japan). Pricing is not publicly disclosed; quotes are provided on contact. No external institutional funding, parent company ownership, or M&A activity is recorded.
EffePharm firmographics
Firmographics- Name
- EffePharm
- Legal name
- EffePharm
- Website
- https://effepharm.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- EffePharm is a Shanghai-based B2B biotechnology company that supplies science-backed bioactive ingredients (NMN, NMNH, and liposomal formulations) and licenses proprietary delivery technologies to nutraceutical, functional food, and personal care brands in 50+ countries.
- Ownership category
- akta.pro rank
EffePharm industry classification
Industry- Product category
- Nutraceutical Bioactive Ingredients
- NAICS
- Chemical and Allied Products Merchant Wholesalers (4246)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Food And Kindred Products (2000)
- akta.pro primary industry
- Condition-Specific Bioactives (Glucosamine/Chondroitin, Plant Sterols, Melatonin, Lutein/Zeaxanthin) (AFAJAKAK)
- akta.pro secondary industry
- Encapsulation & Emulsified Delivery Systems (Spray-dried emulsions, Lipid microencapsulation) (AFAJACAL)
Keywords
Where EffePharm is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Offices2 records
Markets served
EffePharm business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Bulk Ingredient Sales: EffePharm sells bulk bioactive ingredients including NMN, NMNH, and various liposomal formulations directly to nutraceutical brands, supplement manufacturers, and health product companies worldwide. Revenue is generated through per-kilogram pricing of raw materials.
- Technology Licensing: Licensing of proprietary delivery technologies (LipoAvail®, CelleSperse®, EncapCirc®) and trademarked ingredient brands to formulation partners. 'Uth' series trademarks licensed to over 110+ brands globally.
- Customized Formulation Services: Provides customized solutions and formulation development services for clients with specific product requirements, including scientific advisory support and marketing strategy assistance.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
EffePharm product offering
Product offeringCore offering
EffePharm manufactures and sells bulk bioactive ingredients (including NMN, NMNH, liposomal nutrient formulations, Biofolate®, SuperMide™, ErgoX™, Fisetin, PEA, and Trigonelline) to nutraceutical, functional-food, and personal-care brands globally. The company also licenses proprietary delivery technologies (LipoAvail®, CelleSperse®, EncapCirc®) and the 'Uth' trademark series to 110+ brands and provides customized formulation services to clients in 50+ countries.
Product overview
EffePharm is a biotechnology company specializing in science-backed bioactive ingredients for healthy aging, human nutrition, and personal care. The company operates a unified platform-plus-modules architecture built around its Effe-PLUS Platform, which includes three proprietary delivery technologies: LipoAvail® Liposomal Technology, CelleSperse® Micelles Technology, and EncapCirc® Microencapsulation Technology. The core product portfolio centers on NAD+ boosters, with flagship brands UTHEVER® NMN (world's first clinically proven NMN) and UthPeak® NMNH (world's first, largest, and longest human clinical trial on reduced NMN with Self-GRAS status). The LipoAvail® platform powers multiple liposomal sub-brands including Liposomal NMN, NAD+, Vitamin C, Curcumin, Coenzyme Q10, Iron, PEA, Silymarin, Resveratrol, and Glutathione—each claiming significant bioavailability improvements over regular forms. Additional ingredients include Biofolate® Folic Acid, Fisetin, SuperMide™ Spermidine, ErgoX™ Ergothioneine, and Palmitoylethanolamide (PEA). Products are sold in bulk to B2B clients (nutritional supplement, food, beverage, personal care brands) across 50+ countries.
Differentiator
Problem solved
Functional benefit
Brands
- UTHEVER: World's first clinically proven NMN brand and No.1 trademarked NMN ingredient brand in the USA
- UthPeak
- LipoAvail
- CelleSperse
- EncapCirc
- ApiAge
- SuperMide
- ErgoX
- Biofolate
- Effe-PLUS Platform
Products and services
- UTHEVER® NMN
Quantifiable outcome
- 3X increase in NAD+ levels after 90 days of UthPeak® NMNH supplementation (Phase I clinical trial)
- +11 more outcomes
Companies that use EffePharm
Customer profileSegments3 records
Ideal customer profiles3 records
EffePharm technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
EffePharm partnerships and signals
Strategic signalScale indicators6 records
Recent moves6 records
Expansion highlights6 records
EffePharm competitors and assessment
Company assessmentDirect peers
- ChromaDex: ChromaDex is a direct peer as the leading B2B supplier of NAD+ precursor ingredients (notably Niagen/NR), serving the same nutraceutical and supplement brands with a comparable patented-ingredient licensing model. Both compete for the same anti-aging customer base.
- Sabinsa Corporation: Sabinsa is a closely comparable peer as a B2B supplier of clinically supported, patented nutraceutical ingredients (botanical extracts and bioactives) with strong regulatory dossiers. Both sell branded ingredients under trademark protection to global supplement brands.
- AIDP Inc. AIDP is a direct peer as a US-based B2B distributor of branded, science-backed nutraceutical ingredients (including vitamins, minerals, and bioactives) to supplement manufacturers. Both compete for the same formulator customers with proprietary ingredient brands.
- Bioiberica: Bioiberica is a direct peer specializing in bioactive ingredients derived from natural sources (collagen, heparin, glucosamine, chondroitin) sold B2B to global supplement and pharma brands. Both operate a science-driven, branded-ingredient model targeting joint health and healthy aging.
- Nutraceutix: Nutraceutix is a direct peer offering proprietary delivery technologies (including BIO-tract and other controlled-release platforms) for probiotics and bioactives in the nutraceutical industry. It competes with EffePharm's Effe-PLUS delivery platform on technology licensing to supplement brands.
Broad incumbents
- Glanbia Nutritionals: Glanbia Nutritionals is a broad incumbent that sells a wide portfolio of functional and nutritional ingredients to supplement and food manufacturers. It competes with EffePharm in the liposomal and bioactive delivery ingredient space but across a much broader category set.
- Lonza Group: Lonza is a broad incumbent with a large nutraceutical and capsule ingredients business serving global supplement and nutrition brands. It offers overlapping lipid-based and specialty delivery formats but operates across a much wider ingredient portfolio.
- DSM-Firmenich: DSM-Firmenich is a broad incumbent in nutritional ingredients (vitamins, omega-3s, carotenoids) with deep R&D and global regulatory reach. It overlaps with EffePharm in liposomal vitamin and bioactive categories but as part of a much larger portfolio.
Emerging players
- NOVOS Labs: NOVOS is an emerging player in the longevity supplement space that formulates products using NMN and other NAD+ precursors. It is a downstream customer and partial competitor to EffePharm, sourcing NMN ingredients for its own branded formulations.
- Quicksilver Scientific: Quicksilver Scientific is an emerging player focused on liposomal and nanoliposomal delivery technologies for nutraceutical and pharmaceutical actives. It is a partial overlap on the LipoAvail delivery platform concept but primarily sells finished consumer products.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
EffePharm social profiles
Digital presenceEffePharm compliance and trust
Trust signalCompliance6 records
EffePharm financial estimates
Financial estimateRevenue estimate
Valuation estimate
EffePharm leadership team
Management profileNumber of profiles
Profiles2 records
EffePharm funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EffePharm M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EffePharm
What does EffePharm do?
EffePharm manufactures and sells bulk bioactive ingredients (including NMN, NMNH, liposomal nutrient formulations, Biofolate®, SuperMide™, ErgoX™, Fisetin, PEA, and Trigonelline) to nutraceutical, functional-food, and personal-care brands globally. The company also licenses proprietary delivery technologies (LipoAvail®, CelleSperse®, EncapCirc®) and the 'Uth' trademark series to 110+ brands and provides customized formulation services to clients in 50+ countries.
Is EffePharm a public or private company?
EffePharm is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was EffePharm founded?
EffePharm was founded in 2017. It employs 11 to 50 people.
Where is EffePharm based?
EffePharm is headquartered in Shanghai, China, in the Asia region.
How does EffePharm make money?
Three revenue lines are on record. Bulk Ingredient Sales are the primary driver. The others are technology Licensing and customized Formulation Services.
Who are EffePharm's main competitors?
Direct peers on record are ChromaDex, Sabinsa Corporation, AIDP Inc., Bioiberica and Nutraceutix. Broad incumbents are Glanbia Nutritionals, Lonza Group and DSM-Firmenich. Emerging players are NOVOS Labs and Quicksilver Scientific.
Does EffePharm have an API?
No public API is recorded for EffePharm.
What industry is EffePharm in?
EffePharm's product category is Nutraceutical Bioactive Ingredients. Its primary akta.pro industry code is AFAJAKAK, Condition-Specific Bioactives (Glucosamine/Chondroitin, Plant Sterols, Melatonin, Lutein/Zeaxanthin), with a secondary code of AFAJACAL, Encapsulation & Emulsified Delivery Systems (Spray-dried emulsions, Lipid microencapsulation). Its NAICS code is 4246 and its SIC code is 2833.